<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514562</url>
  </required_header>
  <id_info>
    <org_study_id>VS-001</org_study_id>
    <nct_id>NCT04514562</nct_id>
  </id_info>
  <brief_title>The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes: CLEAR Study</brief_title>
  <official_title>Prospective, Open-Label, Multi-Center Single-Arm Trial Designed to Assess the Safety, Performance and Efficacy of the NeVa Stent Retriever in the Treatment of Large Vessel Occlusion Strokes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vesalio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vesalio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open label, single-arm 90-day study designed to assess the safety, performance&#xD;
      and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the&#xD;
      NeVa stent retrievers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open label, multi-center, single-arm trial designed to assess the&#xD;
      safety, performance and efficacy of the NeVa stent retriever in the treatment of large vessel&#xD;
      occlusion strokes. Up to 120 eligible subjects at up 20 sites will participate in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recanalization rate of the occluded target vessel</measure>
    <time_frame>During the procedure/surgery</time_frame>
    <description>Recanalization rate of the occluded target vessel (defined by an eTICI score ≥ 2b) following three or less passes using the NeVa device(s).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>NeVa Stent Retrievers</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeVa Stent Retrievers</intervention_name>
    <description>mechanical neurothrombectomy</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke,&#xD;
             and subject belongs to one of the following subgroups:&#xD;
&#xD;
             1.1. Subject has failed IV t-PA therapy&#xD;
&#xD;
             1.2. Subject is contraindicated for IV t-PA administration&#xD;
&#xD;
             1.3. IV-tPA given within 3 hours of symptom onset&#xD;
&#xD;
          2. Age ≥18 and ≤ 85&#xD;
&#xD;
          3. NIHSS score ≥ 8 and ≤ 25&#xD;
&#xD;
          4. Prestroke mRS score of ≤ 1&#xD;
&#xD;
          5. Intracranial arterial occlusion of the distal intracranial carotid artery or middle&#xD;
             cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery&#xD;
             (PCA), basilar artery, or vertebral artery demonstrated with DSA.&#xD;
&#xD;
          6. Thrombectomy procedure can be initiated within 8 hours from symptom onset (defined as&#xD;
             time last known well [TLKW]) and at least one NeVa pass occurring within 8 hours&#xD;
&#xD;
          7. Imaging Inclusion Criteria:&#xD;
&#xD;
             7.1. Non-Contrast CT Selection (if CT Perfusion or MRI not utilized): ASPECTS 6-10 ,&#xD;
             or&#xD;
&#xD;
             7.2. CT Perfusion core ≤50 cc, or&#xD;
&#xD;
             7.3. MRI DWI core ≤50 cc&#xD;
&#xD;
          8. Subject or legal representative is able and willing to give informed consent prior to&#xD;
             the intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-existing medical neurological or psychiatric disease that would confound the&#xD;
             neurological or functional evaluations, e.g. dementia with prescribed&#xD;
             anti-cholinesterase inhibitor (e.g. Aricept).&#xD;
&#xD;
          2. Cardiopulmonary resuscitation, cardiac arrhythmia resulting in hemodynamic instability&#xD;
             (hypotension) that is not easily medically correctable, evidence of ongoing myocardial&#xD;
             infarction, concern for pre-treatment pulmonary aspiration.&#xD;
&#xD;
          3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.&#xD;
&#xD;
          4. Cerebral vasculitis&#xD;
&#xD;
          5. History of severe allergy to contrast medium.&#xD;
&#xD;
          6. Known allergy to NeVa materials (nitinol, stainless steel);&#xD;
&#xD;
          7. Suspicion of aortic dissection, septic embolus, or bacterial endocarditis&#xD;
&#xD;
          8. Systemic infection&#xD;
&#xD;
          9. Significant mass effect with midline shift&#xD;
&#xD;
         10. Evidence of intracranial tumor (except small meningioma [≤ 3 cm])&#xD;
&#xD;
         11. Any CT or MRI evidence of acute hemorrhage products on presentation.&#xD;
&#xD;
         12. Inability to deploy NeVa device for at least one pass for any other reason&#xD;
&#xD;
         13. Life expectancy less than 6 months&#xD;
&#xD;
         14. Any other condition that, in the opinion of the investigator, precludes an&#xD;
             endovascular procedure or poses a significant hazard to the subject if an endovascular&#xD;
             procedure was performed.&#xD;
&#xD;
         15. Females you are pregnant or breastfeeding.&#xD;
&#xD;
         16. Active malignancy&#xD;
&#xD;
         17. Stenosis or occlusion in a proximal vessel requiring treatment or preventing access to&#xD;
             the thrombus.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kathleen Calderon</last_name>
    <phone>615-206-7788</phone>
    <email>kcalderon@vesalio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vascular Neurology of Southern California</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asif Taqi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Health Research Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Hanel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>WellStar System Inc</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rishi Gupta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Community Hospital</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aamir Badruddin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center Dept of Diagnostic Radiology &amp; Nuclear Med.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Miller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fort Sanders Regional</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Woodward, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Maud, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

